ArticleJournal of thoracic disease2025
Management and survival outcomes of patients with postoperative recurrence of non-small cell lung cancer at isolated ipsilateral hilar or mediastinal lymph node.
Article in Journal of thoracic disease, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Current guidelines recommend chemoradiotherapy or chemotherapy alone in cases of prior radiotherapy for mediastinal lymph node (LN) recurrence after surgery for non-small cell lung cancer (NSCLC). However, data on management and outcomes remain limited. This study investigated treatment approaches and survival outcomes in patients with isolated ipsilateral hilar or mediastinal LN recurrence after surgical resection for NSCLC. Methods: A retrospective chart review was conducted using a multi-institutional database to identify consecutive patients with isolated ipsilateral hilar or mediastinal LN recurrence after surgical resection for NSCLC between 2014 and 2016 at 10 institutions. Patient characteristics, recurrence treatment, and post-recurrence survival (PRS) were analyzed. Results: Sixty-seven patients were included, with a median age of 72 years and a median follow-up of 51.5 months. Two- and 5-year PRS rates were 69.2% and 34.2%, respectively. Local radical therapy (LRT) (surgical resection or radiotherapy), chemotherapy, and chemoradiotherapy were administered in 16 (24%), 30 (45%), and 21 (31%) patients, respectively. Among those receiving chemotherapy, cytotoxic drugs, tyrosine kinase inhibitor (TKI), and immune checkpoint inhibitor (ICI) with or without cytotoxic drugs were administered in 12, 11, and 7 patients, respectively. Five-year PRS rates in patients receiving LRT, chemotherapy, and chemoradiotherapy were 32.9%, 12.6%, and 55.0%, respectively. Conclusions: Our data suggest that various treatments are administered for postoperative recurrence at isolated ipsilateral hilar or mediastinal LN, differing from current guideline recommendations, which is associated with acceptable survival outcomes. Multidisciplinary discussions are essential for optimizing management.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.